Idec, Corixa file suits
CRXA and partner GlaxoSmithKline (GSK; LSE:GSK) said they filed suit on Wednesday against IDPH in the U.S. District Court for the District of Delaware alleging that IDPH's Zevalin radioimmunotherapy infringes three CRXA patents. CRXA's suit follows two suits filed on Tuesday by IDPH in the U.S. District Court for the Southern District of California: one suit against CRXA, CRXA's Coulter Pharmaceuticals subsidiary and the University of Michigan seeking a declaration that Zevalin does not infringe CRXA's radioimmunotherapy patents, and another against GSK seeking a declaration that IDPH's manufacture of Zevalin does not infringe GSK's patents related to cell culture media.
Both Zevalin and Bexxar radioimmunotherapy, developed by CRXA's Coulter Pharmaceutical subsidiary, are under FDA review to treat non-Hodgkin's lymphoma (NHL). Both products target CD20 but use different radiolabels. ...